Company Overview: AMGN

AMGN Overview

Upcoming Projects (AMGN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (AMGN)

2: Discussing the potential of rocatinlimab, an investigational therapy targeting the OX40 receptor, for adults with moderate to severe atopic dermatitis and the recently announced top-line results of the Phase 3 ROCKET HORIZON trial.
Tickers: KYKOF, AMGN
Executed On: Oct 15, 2024 at 09:40 AM EDT
Discussing the potential of rocatinlimab, an investigational therapy targeting the OX40 receptor, for adults with moderate to severe atopic dermatitis and the recently announced top-line results of the Phase 3 ROCKET HORIZON trial.
Tickers: KYKOF, AMGN
Executed On: Oct 10, 2024 at 01:00 PM EDT
Discussing the potential of UPLIZNA (inebilizumab-cdon), an anti-CD19 mAb, for patients with generalized Myasthenia Gravis and the publicly available results from the Phase 3 MINT trial
Ticker: AMGN
Executed On: Oct 07, 2024 at 08:00 AM EDT
A Third Look: Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Tickers: AMGN, AZN
Executed On: Jul 23, 2024 at 04:30 PM EDT
A Second Look: Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Tickers: AZN, AMGN
Executed On: Jul 22, 2024 at 11:00 AM EDT
Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Tickers: AMGN, AZN
Executed On: Jul 15, 2024 at 04:00 PM EDT
A Third look: Discussing the topline results for Uplinza (inebilizumab) for treatment of Immunoglobin G4-related disease (IgG4-RD)
Ticker: AMGN
Executed On: Jun 28, 2024 at 05:00 PM EDT
A second look: Discussing the topline results for Uplinza (inebilizumab) for treatment of Immunoglobin G4-related disease (IgG4-RD)
Ticker: AMGN
Executed On: Jun 26, 2024 at 12:30 PM EDT
Discussing the topline results for Uplinza (inebilizumab) for treatment of Immunoglobin G4-related disease (IgG4-RD)
Ticker: AMGN
Executed On: Jun 25, 2024 at 03:30 PM EDT
A Second Look: Discussing the impact of a price ceiling imposed on the arthritis drug Enbrel (etanercep) by Colorado’s Prescription Drug Affordability Board.
Ticker: AMGN
Executed On: Apr 12, 2024 at 02:00 PM EDT
Discussing the impact of a price ceiling imposed on the arthritis drug Enbrel (etanercep) by Colorado’s Prescription Drug Affordability Board.
Ticker: AMGN
Executed On: Apr 04, 2024 at 03:00 PM EDT
A Third View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Mar 04, 2024 at 06:30 PM EST
A Second View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Feb 29, 2024 at 10:30 AM EST
Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Feb 07, 2024 at 02:00 PM EST
A Third look: Discussing the recent label expansion of TEPEZZA (teprotumumab-trbw) for patients with TED, regardless of disease activity or duration.
Ticker: AMGN
Executed On: Dec 19, 2023 at 10:00 AM EST
A Second look: Discussing the recent label expansion of TEPEZZA (teprotumumab-trbw) for patients with TED, regardless of disease activity or duration.
Ticker: AMGN
Executed On: Dec 14, 2023 at 05:00 PM EST
Discussing the recent label expansion of TEPEZZA (teprotumumab-trbw) for patients with TED, regardless of disease activity or duration.
Ticker: AMGN
Executed On: Nov 30, 2023 at 09:30 AM EST
A Second Look: Discussing the potential of Amgen's KRAS-G12C- inhibitor, sotorasib, in KRAS G12C-mutated mCRC and the results from the CodeBreak 300 phase III study presented at the 2023 ESMO conference.
Ticker: AMGN
Executed On: Nov 01, 2023 at 08:00 AM EDT
A Second Look: Discussing the current standard of care for high LP(a) and the recent phase 2 results of Amgen's Olpasiran
Ticker: AMGN
Executed On: Sep 27, 2023 at 01:00 PM EDT
Discussing the current standard of care for high LP(a) and the recent phase 2 results of Amgen's Olpasiran
Ticker: AMGN
Executed On: Sep 14, 2023 at 09:00 AM EDT
Discussing the results from the Phase 1b CodeBreaK 101 study of Amgen's Lumakras (Sotorasib) combined with Vectibix (Panitumumab), for treating patients with colorectal cancer
Ticker: AMGN
Executed On: Sep 08, 2023 at 06:00 PM EDT
A Third Look: Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, ABBV, BMY, AMGN, LLY
Executed On: Jul 20, 2023 at 04:00 PM EDT
A Second Look: Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, LLY, AMGN, ABBV, BMY
Executed On: Jul 14, 2023 at 11:00 AM EDT
A discussion of the KRAS G12C NSCLC landscape, including commercial assets and the AACR data updates from GDC-6036, LY3537982, and IBI351.
Tickers: AMGN, MRTX
Executed On: May 26, 2023 at 02:00 PM EDT
Examining the potential of Eli Lillys' KRAS G12C inhibitor, LY3537982, in KRAS G12C–mutant advanced solid tumors with a focus on the Phase 1 LOXO-RAS-20001 study presented at AACR 2023
Tickers: LLY, AMGN, MRTX
Executed On: Apr 25, 2023 at 04:30 PM EDT
A third look: Discussing the potential of TEPEZZA (teprotumumab-trbw) in chronic thyroid eye disease(TED) and it's current role in TED treatment landscape.
Tickers: AMGN, HZNP
Executed On: Apr 19, 2023 at 06:00 PM EDT
A second look: Discussing the potential of TEPEZZA (teprotumumab-trbw) in chronic thyroid eye disease(TED) and it's current role in TED treatment landscape.
Tickers: AMGN, HZNP
Executed On: Apr 17, 2023 at 08:00 AM EDT
Discussing the potential of TEPEZZA (teprotumumab-trbw) in chronic thyroid eye disease(TED) and it's current role in TED treatment landscape.
Tickers: AMGN, HZNP
Executed On: Apr 14, 2023 at 11:00 AM EDT
A second look at the Phase 2 data of Horizon's dazodalibep for Sjögren’s Syndrome
Tickers: HZNP, AMGN
Executed On: Feb 14, 2023 at 11:00 AM EST
A look at the Phase 2 data of Horizon's dazodalibep for Sjögren’s Syndrome
Tickers: AMGN, HZNP
Executed On: Feb 07, 2023 at 01:00 PM EST
Discussing the standard of care and the potential of AMG 133, a bi-specific GIPR antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule, currently in development by Amgen for the treatment of obesity.
Ticker: AMGN
Executed On: Dec 12, 2022 at 11:00 AM EST
Discussing the potential of Obe-cel(AUTO1), a CD19 CAR T cell therapy being investigated for treatment in adult patients with acute lymphoblastic leukemia(ALL) and it's ongoing Phase 1/2 FELIX trial
Tickers: AUTL, AMGN, GILD, PFE
Executed On: Oct 07, 2022 at 02:00 PM EDT
A look at the phase 3 CodeBreak 200 trial of Lumakras' (sotorasib) superior progression-free survival over Docetaxel presented at the ESMO 20222 Conference in NSCLC
Ticker: AMGN
Executed On: Sep 27, 2022 at 10:15 AM EDT
A Fourth look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, NVS, IONS
Executed On: Aug 18, 2022 at 04:00 PM EDT
A third look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, ARWR, NVS, IONS, REGN, SNY
Executed On: Aug 17, 2022 at 04:30 PM EDT
A second look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Tickers: AMGN, NVS, IONS, SLN, REGN, ESPR
Executed On: Aug 17, 2022 at 10:15 AM EDT
A look at Amgen's OCEAN(a) study and potential of olpasiran for treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Ticker: AMGN
Executed On: Jul 07, 2022 at 06:30 PM EDT
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 4th look
Tickers: AMGN, AZN
Executed On: Mar 23, 2022 at 02:45 PM EDT
A Third View: Discussing the potential of Amgen's LUMAKRAS (sotorasib) in 2nd-line NSCLC with KRAS G12C mutation.
Ticker: AMGN
Executed On: Mar 22, 2022 at 10:00 AM EDT
A Second View: Discussing the potential of Amgen's LUMAKRAS (sotorasib) in 2nd-line NSCLC with KRAS G12C mutation.
Ticker: AMGN
Executed On: Mar 18, 2022 at 05:30 PM EDT
Discussing the potential of Amgen's LUMAKRAS (sotorasib) in 2nd-line NSCLC with KRAS G12C mutation.
Ticker: AMGN
Executed On: Mar 18, 2022 at 02:00 PM EDT
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 3rd look
Tickers: AMGN, AZN
Executed On: Mar 16, 2022 at 12:30 PM EDT
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 2nd look
Tickers: AMGN, AZN
Executed On: Mar 03, 2022 at 01:00 PM EST
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 1st look
Tickers: AMGN, AZN
Executed On: Feb 23, 2022 at 04:00 PM EST

Upcoming & Overdue Catalysts (AMGN)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (AMGN)

Don’t see a strategic initiative related to the company you care about? Create your own!